Samsung Biologics
207940
Performance
About Samsung Biologics
Samsung Biologics is a leading global CDMO providing end-to-end biologics development, CGMP manufacturing, and aseptic fill/finish services for biopharma partners worldwide. The company specializes in turning early-stage biologics programs into scalable clinical and commercial manufacturing solutions, supported by multiple CGMP facilities and integrated development capabilities. Headquartered in Incheon, South Korea, Samsung Biologics serves clients across the biopharma industry with a focus on speed, quality, and global supply chain integrity.
Recent News
Executing Biologics Technology Transfer Through Integrated Operating Models
Samsung Biologics Workers Begin Five-Day Strike over Wage Disputes
WuXi Biologics Tops Out Singapore CRDMO Hub, Adding 120k Liters Capacity
Samsung Biologics Estimates US$100 Million Strike Loss as Unions Press Demands
Samsung Biologics Q1 Profit Jumps 46% as Biopharma Demand Surges, but Labor Unrest Looms
Pharma’s Manufacturing Reconfigurations Provide CDMOs with Expansion Opportunities